Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Bone health, fracture risk, and Multiple Sclerosis: a UK Biobank study
Multiple Sclerosis
P4 - Poster Session 4 (5:30 PM-6:30 PM)
9-009

To examine the impact of Multiple Sclerosis on bone health and explore mechanisms for this association.


People with MS (PwMS) have an increased risk of osteoporosis and fractures; this is thought to be related to shared risk factors, although has not been confirmed. 


Using  well described exposures, we investigated associations with heel Bone Mineral Densitometry (BMD) and fractures in PwMS in UK Biobank. We used heel BMD from 960 people with MS and 278,138 controls, and 47,466 fractures in 502,583 individuals. 


Multivariate linear (heel BMD) or logistic (fracture) regression adjusting for age, sex, ethnicity and current deprivation status was performed. Likelihood ratio test was used to assess model fit. 


Demographic characteristics were representative of the MS population (F:M ratio 2.58:1, mean age 55.2 SD 7.6). 234/1781 PwMS in UK Biobank (13.1%) reported fractures Heel BMD T-scores were lower among PwMS (mean -0.649+/-1.3 vs -0.336+/-1.24). 


Lower heel BMD was associated with smoking (beta -0.1), alcohol consumption (beta -0.03), later menarche (beta -0.03), post-menopausal status (beta -0.18), epilepsy (beta -0.28,), and vitamin D supplementation (beta -0.1). 


In a model incorporating all individually-significant predictors, the effect of MS on BMD attenuated slightly (beta -0.11, 95%CI -0.19 to -0.02) while the effect of MS on fracture risk reversed (OR 0.81, 95% CI 0.69-0.95). To determine which exposure explained this association, we built models for each significant predictor and MS status. After adjustment for falls, the effect of MS on fracture attenuated (OR 0.90, 95% CI 0.78 to 1.04). No other exposures altered this association. 


These results confirm in a large cohort that MS is associated with lower BMD and higher risk of bone fractures. No single factor studied appears to explain the reduced BMD in MS; however increased rates of fracture appear to be driven by both decreased BMD and increased frequency of falls. 


Authors/Disclosures
Sara Leddy, MBBS
PRESENTER
No disclosure on file
No disclosure on file
Gavin Giovannoni, MD (QMUL) Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.
Ruth Dobson (Queen Mary University London) The institution of Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. The institution of Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . The institution of Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. The institution of Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. The institution of Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Ruth Dobson has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis . Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sandoz. Ruth Dobson has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Epionex. The institution of Ruth Dobson has received research support from NMSS. The institution of Ruth Dobson has received research support from MS Society UK . The institution of Ruth Dobson has received research support from BMA Foundation . The institution of Ruth Dobson has received research support from Biogen . The institution of Ruth Dobson has received research support from Merck . The institution of Ruth Dobson has received research support from Horne Family Charitable Trust . The institution of Ruth Dobson has received research support from MRC. The institution of Ruth Dobson has received research support from NIHR. Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Medscape . Ruth Dobson has received personal compensation in the range of $0-$499 for serving as a Speaker with Limbus. Ruth Dobson has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Neurology Academy .